Featured here, the Income Statement (earnings report) for Galera Therapeutics Inc, showing the company's financial performance from operating and non operating activities such as revenue ...

The average one-year price target for Galera Therapeutics (NASDAQ:GRTX) has been revised to 0.38 / share. This is an increase of 7.14% from the prior estimate of 0.36 dated October 31, 2023.

This article Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying originally appeared on Benzinga.com.

Galera Therapeutics shares are trading lower by 34.8% during Monday's session. The company said its shares will be delisted due to non-compliance with Nasdaq's continued listing standards.

Company reports second quarter 2024 financial resultsMALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company ...

Galera Therapeutics (OTC:GRTX), Inc. (OTC Pink Market:GRTX) held a Special Meeting of Stockholders on Thursday, where attendees voted against the proposed liquidation and dissolution of the company.

Short interest in Galera Therapeutics Inc (OTC:GRTX) increased during the last reporting period, rising from 5.28K to 5.46K. This put 0.01% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Upgrade your Yahoo Finance plan to get complete details for Galera Therapeutics, Inc. Get advanced tools and insights to navigate the markets.

Galera Therapeutics (OTC:GRTX), Inc. (OTC Pink Market:GRTX) held a Special Meeting of Stockholders on Thursday, where attendees voted against the proposed liquidation and dissolution of the company.